Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Catalyst Pharmaceuticals Inc | CPRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 15.20 | 06:32:56 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 15.20 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 1 | - | 11.09 - 17.765 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 04:35:32 | 1 | US$ 15.59 | USD |
Catalyst Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.79B | 117.86M | - | 398.2M | 71.41M | 0.61 | 25.09 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Catalyst Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CPRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.87 | 15.52 | 14.585 | 15.02 | 955,870 | 0.33 | 2.22% |
| 1 Month | 15.54 | 16.25 | 14.585 | 15.26 | 1,313,181 | -0.34 | -2.19% |
| 3 Months | 13.32 | 17.495 | 13.1161 | 15.41 | 1,353,159 | 1.88 | 14.11% |
| 6 Months | 12.65 | 17.495 | 12.27 | 14.88 | 1,387,685 | 2.55 | 20.16% |
| 1 Year | 16.92 | 17.765 | 11.09 | 13.96 | 1,476,825 | -1.72 | -10.17% |
| 3 Years | 4.57 | 22.11 | 4.43 | 12.42 | 1,616,173 | 10.63 | 232.60% |
| 5 Years | 5.68 | 22.11 | 2.235 | 8.70 | 1,763,849 | 9.52 | 167.61% |
Catalyst Pharmaceuticals Description
| Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
